{"_id":"XLiMrj2b5u3GjfVI3DOVA5yhG0c9CObZfiNWwRagIvSnMZMZg1q383","lastupdate":"2025-01-30T00:00:00.000Z","update_date":"2025-01-30T00:00:00.000Z","lastModified":"Jan 30, 2025","active":1,"confidence_score":72,"confidence_score_reason":"sector, tags, video or image, markets, not claimed","urlname":"averna-therapeutics","minimal_profile":0,"status":"","fullstatus":"","acquired":null,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$7acWD1R0tEO7bZlGuNhDvprDs38SR5zo7nSZjsqx83cGMkbyLu0hyr","name":"Averna Therapeutics","oneliner":"Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA","registrar":"516545126","website":"https://avernatx.com/","careerspage":"","founded_month":1,"founded_year":2022,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/103303080","instagram":""},"social":["https://www.linkedin.com/company/103303080"],"flattenedsociallinks":"https://www.linkedin.com/company/103303080","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":51,"patent":null,"raised":82000000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Exsilio"],"about":"Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's proprietary technology focuses on inserting therapeutic genetic instructions into specific \"safe harbor\" regions of the genome. These regions are selected to allow stable gene integration without disrupting normal cellular functions. By encoding their medicines in RNA, Averna utilizes validated, non-viral delivery platforms that are designed to be safe, efficient, scalable, and cost-effective. This approach also permits redosing with the intent to achieve curative outcomes.","climatetech_description":null,"is_climatetech_relevant":null,"phone":null,"country":"Israel","address":{"israeli":[{"id":"W6a3bCte8wGkqAYychuWzsGk9MU5b04Se44cndh0S73oqfz6EPLWsU","city":"Ness Ziona","type":null,"address":"Ilan Ramon St, Ness Ziona, Israel","placeid":"ChIJJ5Okcu62AhURIq5bRaBvBPQ","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"Snn6n3XFNxEsTQvd0cbQSjQMgi0HvAsc3aMwAjBr4RwRZqabTDm4y3","date":"Jan 28, 2025","link":"https://en.globes.co.il/en/article-tal-zaks-israeli-startup-targets-rare-genetic-diseases-1001500636","source":"en.globes.co.il","visible":1,"analysis":{"tags":"gene editing","round":"Series A","company":"Averna Therapeutics","layoffs":null,"summary":"Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A financing round. The company is led by Dr. Tal Zaks, former chief medical officer at Moderna, and is developing a novel approach to gene editing using mRNA technology to treat rare genetic diseases. The company aims to move to the preclinical trial stage with its technology, which has garnered interest due to its potential to treat a variety of diseases, including cancer and autoimmune disorders. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas approach.","partners":null,"customers":null,"eventType":null,"investors":"CRISPR Therapeutics","confidence":9,"key_topics":["gene editing","investment","mRNA technology","rare diseases","CRISPR"],"date_of_event":"January 28, 2025","product_stage":"preclinical trial","investment_date":"last summer","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$82 million","structured_issues":["Investment","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"N4GfPChT5i7rJ1KodcR4LFG5qV9A81n3ibXgK3H9aml6sAduZZJW2T","news_summary":"The former Moderna CMO, who led development of the company's Covid vaccine, tells \"Globes\" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qlahPbuoAeLVXJVHr1EE9nRbBMsszD5AZ59q7qc2fJkZWyjUQx5w2n","date":"Jan 28, 2025","link":"https://en.globes.co.il/en/article-tal-zaks-israeli-startup-targets-rare-genetic-diseases-1001500636","source":"en.globes.co.il","visible":1,"analysis":{"tags":"gene editing","round":"Series A","company":"Averna Therapeutics","layoffs":null,"summary":"Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A round. The company is led by Dr. Tal Zaks, former CMO of Moderna, and is developing a new approach to gene editing using mRNA technology. The company aims to treat rare genetic diseases and potentially develop drugs for cancer and autoimmune diseases. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas potential. The company is in the preclinical trial stage and plans to keep research in Israel while sharing development with the US.","partners":null,"customers":null,"eventType":null,"investors":"CRISPR Therapeutics","confidence":9,"key_topics":["gene editing","investment","mRNA technology","CRISPR","biotech"],"date_of_event":"January 28, 2025","product_stage":"preclinical trial","investment_date":"last summer","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$82 million","structured_issues":["Investment","Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Investment  #Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uvQ7cYqFyPsUQZN4FTNJjWTdZxPpb0ubTIQ6ONyjC0SEuJmz9OiA3K","news_summary":"Tal Zaks's Israeli startup targets rare genetic diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"inWw8M25c4KQKTFiEI9JqQut4lK68NQfRhk6JCwK6J4PrYvfZD0Zx4","date":"Jun 25, 2024","link":"https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"investment","company":"Exsilio Therapeutics","layoffs":null,"summary":"Exsilio Therapeutics, a biotechnology company developing genomic medicines, has emerged from stealth with $82 million in Series A financing. The funding round was co-led by Novartis Venture Fund and Delos Capital, with participation from several other investors. Exsilio focuses on creating genomic medicines that use mRNA and lipid nanoparticles to insert genes into safe harbor sites in the human genome. The company aims to treat genetic diseases, cancer, and autoimmune conditions with medicines that can be redosed and titrated. The investment will help Exsilio advance its genomic medicines and select promising lead candidates.","partners":null,"customers":null,"investors":["Novartis Venture Fund","Delos Capital","OrbiMed","Insight Partners","J.P. Morgan Life Sciences Private Capital","CRISPR Therapeutics","Innovation Endeavors","Invus","Arc Ventures","Deep Insight"],"confidence":10,"key_topics":["genomic medicines","Series A","mRNA","lipid nanoparticles","genetic diseases"],"date_of_event":"2023-10-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":82000000,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PcSzulIJDAVUo59f7md6XgjvoVHMCLDv3o7nuOSW48W7iUpXit2YsZ","news_summary":"Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":3,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pharmaceuticals","healthcare"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B","B2C"],"productstage":"Released","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":10,"lastfunding":"$82M","totalrounds":1,"fundingstage":"A","totalfunding":"$82M","publicinvestors":10,"lastpublicfunding":82000000,"totalpublicrounds":1,"totalpublicfunding":82000000},"team":[{"name":"Devin Trudeau","email":"devint@avernatx.com","phone":"","gender":"Male","userid":"zGpSBHtjBBJcB9Hrb0ZqoDkL46vS2pIblIMAVHUK8w0fvTs6at5eCh","bounced":false,"claimed":null,"founder":0,"urlname":"devin-trudeau","visible":1,"memberid":"RNOc0QMRF5eH3CmqnYJDAxlJHOdSY7NEFMABuptOjqltMy09TrclVG","position":"Director of Molecular Engineering","last_name":"Trudeau","claimtoken":"jz817kiDhe5ycywEXN3g0OhewOekCjpska236gzPwFgx9oUC56msmG","first_name":"Devin","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/devintrudeau/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2025-01-30 11:54:21.000000","initials":"DT","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ira Gotliv","email":"irag@avernatx.com","phone":"","gender":"Female","userid":"URVRmh37pyUl41TmsnuDNuBwrF10xeEnRtO3ivG9tu3l9EMStNYVO2","bounced":false,"claimed":null,"founder":0,"urlname":"ira-gotliv","visible":1,"memberid":"Z2gtembe3A0Qa9Vk6K2IjUuZsBmKjiwA4fces7meXHf0oBH4A6v77y","position":"Director of Preclinical Research","last_name":"Gotliv","claimtoken":"vr84XLZAnkRQ7Hg7xP0uIS6n0JEs6MrCLUi3bpkQumqZj3ShrbBWs3","first_name":"Ira","picturekey":null,"claimeddate":null,"linkedinurl":"https://linkedin.com/in/ira-gotliv-lubarski-0839b410/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2025-01-30 11:54:23.000000","initials":"IG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Pazit Enker Ohana","email":"pazite@avernatx.com","phone":"","gender":"Female","userid":"3WtwpiefCOkW3CjDdPlth15NsRp0DWt76UMqSXOSDyhbbJfDgbBqMs","bounced":false,"claimed":null,"founder":0,"urlname":"pazit-enker-ohana","visible":1,"memberid":"AThheokJ8tj1kcp0owYC1Ib5xqGyGusdQhQ2CbYLM3Cqx4hTxu9pMw","position":"General Manager","last_name":"Enker Ohana","claimtoken":"zka4xZi4QcWfeHXQOtsWxBJB97GCkxO6A1SJPtWV8xKyeaOQd5eEWX","first_name":"Pazit","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/pazit-enker-ohana-68401048/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2025-01-30 11:54:27.000000","initials":"PE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":null,"tag_line_edited":null,"sector":null,"sectorverify":null,"biverify":null,"biverifydate":null,"crunchbaseid":"exsilio-therapeutics","lastupdator":"Jenny Sotnik-Talisman","lastupdator_email":"jenny.sotnik@sncentral.org","creator":"Ido Kilberg","creator_email":"ido@deepinsight.co.il","createdate":"2024-09-16T00:00:00.000Z","biverification":null,"sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"EyKqMsnLSwcy0YcKaHfrCNCB3AIEvZW65HUVzHQpnzBveWaGaIW03v","date":"Jun 2024","amount":"$82M","source":"https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html","eventtype":"FundingRoundEvent","investment":[{"name":"Delos Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/delos-capital","logokey":"$hGHrnBnZZpiCo07lkAXdMTibNBI85Ag8M3YIzLVUAPcgETd8zatgO7.png","tagline":null,"urlname":"/investor_page/delos-capital","isisraeli":0,"investorid":"tF8khsMLG564tZIDzPvHCBVVHU2UqL6X2thOlpNb4zjSu5LTAHyZc8","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4EuGFf4U2kwHmUGuW6vF9GCTTETv2qLsAFGSWNMvXIJQoEDXeiv13M","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hGHrnBnZZpiCo07lkAXdMTibNBI85Ag8M3YIzLVUAPcgETd8zatgO7.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Novartis Venture Fund","type":"Investor","amount":null,"hidden":false,"country":"Switzerland","fullurl":"/investor_page/novartis-venture-fund","logokey":"$BnXTy6DAcaNWzycv1ZO3DKfmbKzLqigYPdcDt7Wqgxm8nRFQY3cZbs","tagline":"","urlname":"/investor_page/novartis-venture-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODRha7kCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"T4tj9E7MxHv2HxWcnsELnAmhEgc8xCUkl5vtDMeRa9wRXvFLnQOM7j","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BnXTy6DAcaNWzycv1ZO3DKfmbKzLqigYPdcDt7Wqgxm8nRFQY3cZbs","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Insight Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/insight-partners","logokey":"$DL56QgFEG8e9HuXHA5roycH0sJYhu3JyCjjxBIkWhPHZ1dpRRHPbIx","tagline":null,"urlname":"/investor_page/insight-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Kr0yfULDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0gaSjMwfITMWRPkTyfHJhKdLF6wut6hxmwfGugYsVPmfEBoJogqcrA","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DL56QgFEG8e9HuXHA5roycH0sJYhu3JyCjjxBIkWhPHZ1dpRRHPbIx","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"CRISPR Therapeutics","type":"Multinational","amount":null,"hidden":true,"country":"United States","fullurl":"/mnc_page/crispr-therapeutics","logokey":"$XutDeystsA4L0BEf2T6u48FDh4wLKescUNvVpTCPaYSENRmdqaEIPj.png","tagline":"Gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.","urlname":"/mnc_page/crispr-therapeutics","isisraeli":0,"investorid":"T2DPt2nULCBVyM0k6NLJdVBcooxQCivdnTkeOX0ajIaxHGtZO8oOt4","fundingtype":"Multinational","leadpartner":null,"investmentid":"32hhnceTxCne6vMtJJtOuZEwKn66aYugkpfGqTeDqtuTOCFMlO2M9W","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XutDeystsA4L0BEf2T6u48FDh4wLKescUNvVpTCPaYSENRmdqaEIPj.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"JPMorgan Chase & Co","type":"Multinational","amount":null,"hidden":false,"country":"United States","fullurl":"/mnc_page/jpmorgan-chase-co","logokey":"$zvcmr1wTvql1Vr018Y9uK1u8VB4x9BnivvCigRqRQ33mLDBe5FIbxI.jpeg","tagline":"Financial Services and Banking","urlname":"/mnc_page/jpmorgan-chase-co","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwK_i_J0KDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"JLe1nugg7jDnY6N0yg5hKvaZMY0LOUChxaJSBGSsJLMPJKMUL7UFPB","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zvcmr1wTvql1Vr018Y9uK1u8VB4x9BnivvCigRqRQ33mLDBe5FIbxI.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Deep Insight","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/deep-insight","logokey":"$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","tagline":null,"urlname":"/investor_page/deep-insight","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PvwjMgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OFigiGvYF2ApcSOebU52vW3p9qr3DJvgdb1X5nOkKPFQpWTuI0hMbq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OrbiMed","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"TgJrLHdCPg09sVIFMmbn7CpnnKJRLMSE77JpdL8hJ2qRvIKcZ4dSI6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Innovation Endeavors","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/innovation-endeavors","logokey":"$4TQKs5g0HnJkWbszwogIexVklK8DsfMdIsUxph58IdxqKTy6Lon5pr","tagline":null,"urlname":"/investor_page/innovation-endeavors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIGY9dwKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"XtiFuR1PmyYEc0uh13SjFEIKsJUCmza8k0OCnfOJypzVoRyC7dMYjq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4TQKs5g0HnJkWbszwogIexVklK8DsfMdIsUxph58IdxqKTy6Lon5pr","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Arc Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/arc-ventures","logokey":"$0sH7WPExFHHV6mUaAaE3eKYe4bI0gBI0oaLwSvMMc5ZGEWoewzdDEV.png","tagline":null,"urlname":"/investor_page/arc-ventures","isisraeli":0,"investorid":"vj3HVHfFjMOUIlo1duK9AH5V8wvzPVcdRwjWLBEyqnj2zcQsaFKsI3","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aNQYy0oxRQcrTWInExnxy8rAxx5vwLeIflOaHFYwsoiAnXhHePVaR0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$0sH7WPExFHHV6mUaAaE3eKYe4bI0gBI0oaLwSvMMc5ZGEWoewzdDEV.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Invus","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/invus","logokey":"$zkaAasvZ0NA9JBeyPq2kxaegtnlXGxyzXibE5iNP8VhQS1Jv8C59gK","tagline":"","urlname":"/investor_page/invus","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2pCrCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"reCmz1lXMyIdoSYxtgi5k5blJXzZlcM8UKLfTdPAsjbQSvFv5yZsHB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zkaAasvZ0NA9JBeyPq2kxaegtnlXGxyzXibE5iNP8VhQS1Jv8C59gK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":82000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2022","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Averna Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$7acWD1R0tEO7bZlGuNhDvprDs38SR5zo7nSZjsqx83cGMkbyLu0hyr","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$7acWD1R0tEO7bZlGuNhDvprDs38SR5zo7nSZjsqx83cGMkbyLu0hyr","seoabout":"Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including g...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"EyKqMsnLSwcy0YcKaHfrCNCB3AIEvZW65HUVzHQpnzBveWaGaIW03v","date":"Jun 2024","amount":"$82M","source":"https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html","eventtype":"FundingRoundEvent","investment":[{"name":"Delos Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/delos-capital","logokey":"$hGHrnBnZZpiCo07lkAXdMTibNBI85Ag8M3YIzLVUAPcgETd8zatgO7.png","tagline":null,"urlname":"/investor_page/delos-capital","isisraeli":0,"investorid":"tF8khsMLG564tZIDzPvHCBVVHU2UqL6X2thOlpNb4zjSu5LTAHyZc8","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4EuGFf4U2kwHmUGuW6vF9GCTTETv2qLsAFGSWNMvXIJQoEDXeiv13M","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hGHrnBnZZpiCo07lkAXdMTibNBI85Ag8M3YIzLVUAPcgETd8zatgO7.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Novartis Venture Fund","type":"Investor","amount":null,"hidden":false,"country":"Switzerland","fullurl":"/investor_page/novartis-venture-fund","logokey":"$BnXTy6DAcaNWzycv1ZO3DKfmbKzLqigYPdcDt7Wqgxm8nRFQY3cZbs","tagline":"","urlname":"/investor_page/novartis-venture-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODRha7kCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"T4tj9E7MxHv2HxWcnsELnAmhEgc8xCUkl5vtDMeRa9wRXvFLnQOM7j","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BnXTy6DAcaNWzycv1ZO3DKfmbKzLqigYPdcDt7Wqgxm8nRFQY3cZbs","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Insight Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/insight-partners","logokey":"$DL56QgFEG8e9HuXHA5roycH0sJYhu3JyCjjxBIkWhPHZ1dpRRHPbIx","tagline":null,"urlname":"/investor_page/insight-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Kr0yfULDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0gaSjMwfITMWRPkTyfHJhKdLF6wut6hxmwfGugYsVPmfEBoJogqcrA","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DL56QgFEG8e9HuXHA5roycH0sJYhu3JyCjjxBIkWhPHZ1dpRRHPbIx","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"CRISPR Therapeutics","type":"Multinational","amount":null,"hidden":true,"country":"United States","fullurl":"/mnc_page/crispr-therapeutics","logokey":"$XutDeystsA4L0BEf2T6u48FDh4wLKescUNvVpTCPaYSENRmdqaEIPj.png","tagline":"Gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.","urlname":"/mnc_page/crispr-therapeutics","isisraeli":0,"investorid":"T2DPt2nULCBVyM0k6NLJdVBcooxQCivdnTkeOX0ajIaxHGtZO8oOt4","fundingtype":"Multinational","leadpartner":null,"investmentid":"32hhnceTxCne6vMtJJtOuZEwKn66aYugkpfGqTeDqtuTOCFMlO2M9W","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XutDeystsA4L0BEf2T6u48FDh4wLKescUNvVpTCPaYSENRmdqaEIPj.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"JPMorgan Chase & Co","type":"Multinational","amount":null,"hidden":false,"country":"United States","fullurl":"/mnc_page/jpmorgan-chase-co","logokey":"$zvcmr1wTvql1Vr018Y9uK1u8VB4x9BnivvCigRqRQ33mLDBe5FIbxI.jpeg","tagline":"Financial Services and Banking","urlname":"/mnc_page/jpmorgan-chase-co","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwK_i_J0KDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"JLe1nugg7jDnY6N0yg5hKvaZMY0LOUChxaJSBGSsJLMPJKMUL7UFPB","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zvcmr1wTvql1Vr018Y9uK1u8VB4x9BnivvCigRqRQ33mLDBe5FIbxI.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Deep Insight","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/deep-insight","logokey":"$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","tagline":null,"urlname":"/investor_page/deep-insight","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PvwjMgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OFigiGvYF2ApcSOebU52vW3p9qr3DJvgdb1X5nOkKPFQpWTuI0hMbq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OrbiMed","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"TgJrLHdCPg09sVIFMmbn7CpnnKJRLMSE77JpdL8hJ2qRvIKcZ4dSI6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Innovation Endeavors","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/innovation-endeavors","logokey":"$4TQKs5g0HnJkWbszwogIexVklK8DsfMdIsUxph58IdxqKTy6Lon5pr","tagline":null,"urlname":"/investor_page/innovation-endeavors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIGY9dwKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"XtiFuR1PmyYEc0uh13SjFEIKsJUCmza8k0OCnfOJypzVoRyC7dMYjq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4TQKs5g0HnJkWbszwogIexVklK8DsfMdIsUxph58IdxqKTy6Lon5pr","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Arc Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/arc-ventures","logokey":"$0sH7WPExFHHV6mUaAaE3eKYe4bI0gBI0oaLwSvMMc5ZGEWoewzdDEV.png","tagline":null,"urlname":"/investor_page/arc-ventures","isisraeli":0,"investorid":"vj3HVHfFjMOUIlo1duK9AH5V8wvzPVcdRwjWLBEyqnj2zcQsaFKsI3","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aNQYy0oxRQcrTWInExnxy8rAxx5vwLeIflOaHFYwsoiAnXhHePVaR0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$0sH7WPExFHHV6mUaAaE3eKYe4bI0gBI0oaLwSvMMc5ZGEWoewzdDEV.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Invus","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/invus","logokey":"$zkaAasvZ0NA9JBeyPq2kxaegtnlXGxyzXibE5iNP8VhQS1Jv8C59gK","tagline":"","urlname":"/investor_page/invus","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2pCrCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"reCmz1lXMyIdoSYxtgi5k5blJXzZlcM8UKLfTdPAsjbQSvFv5yZsHB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zkaAasvZ0NA9JBeyPq2kxaegtnlXGxyzXibE5iNP8VhQS1Jv8C59gK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":82000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}